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Abstract
Abstract
Creutzfeldt-Jakob disease is a rare and fatal neurodegenerative disease. The purpose of this report is to
demonstrate the role of inpatient rehabilitation for a patient recently diagnosed with probable CreutzfeldtJakob disease. A 62-year-old male was readmitted to an acute care hospital after a recent mechanical
fall. For several weeks, he had a constellation of symptoms, including cognitive impairment and
progressive memory loss, gait and postural instability, 20 pounds of unintentional weight loss, visual
hallucinations, myoclonus, and hypophonia. After an extensive workup, a diagnosis of probable
Creutzfeldt-Jakob disease was made, and he was transferred to an acute inpatient rehabilitation hospital.
The patient underwent therapeutic exercise, gait training, neuromuscular reeducation, cognitive behavioral
therapy, and voice therapy during his 14-day rehabilitation stay. The patient progressed from moderate
assistance to minimal assistance with most activities of daily living, bed mobility, and transfers at the
final assessment. He was provided with a rolling walker, home health services, and coordinated care with
physicians at discharge.
This case report highlights the unique challenges of individuals and their families who suffer from prion
disease and reviews ways to manage these barriers through non-pharmacological and pharmacological
treatment options at an inpatient rehabilitation facility. When a diagnosis of probable CJD is made, an
inpatient rehabilitation facility can assist in decreasing the caregiver burden and support the psychosocial
needs of CJD patients while improving physical functioning.
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CASE REPORT

The Management of Newly Diagnosed Probable
Creutzfeldt-Jakob Disease in Acute Rehabilitation
Setting: A Case Report
Royce Copeland a,*, Shefali Amin b, Anthony Donato b
a
b

Baylor College of Medicine, Houston TX, USA
Reading Hospital/Tower Health, Reading PA USA

Abstract
Creutzfeldt-Jakob disease is a rare and fatal neurodegenerative disease. The purpose of this report is to demonstrate
the role of inpatient rehabilitation for a patient recently diagnosed with probable Creutzfeldt-Jakob disease. A 62-yearold male was readmitted to an acute care hospital after a recent mechanical fall. For several weeks, he had a constellation
of symptoms, including cognitive impairment and progressive memory loss, gait and postural instability, 20 pounds of
unintentional weight loss, visual hallucinations, myoclonus, and hypophonia. After an extensive workup, a diagnosis of
probable Creutzfeldt-Jakob disease was made, and he was transferred to an acute inpatient rehabilitation hospital. The
patient underwent therapeutic exercise, gait training, neuromuscular reeducation, cognitive behavioral therapy, and
voice therapy during his 14-day rehabilitation stay. The patient progressed from moderate assistance to minimal
assistance with most activities of daily living, bed mobility, and transfers at the ﬁnal assessment. He was provided with a
rolling walker, home health services, and coordinated care with physicians at discharge.
This case report highlights the unique challenges of individuals and their families who suffer from prion disease and
reviews ways to manage these barriers through non-pharmacological and pharmacological treatment options at an
inpatient rehabilitation facility. When a diagnosis of probable CJD is made, an inpatient rehabilitation facility can assist
in decreasing the caregiver burden and support the psychosocial needs of CJD patients while improving physical
functioning.
Keywords: CJD, Creutzfeldt-Jakob disease, Prion disease management, Rehabilitation, Neurodegenerative, Dementia

1. Introduction

P

atients with dementia can cause a signiﬁcant
burden on caregivers, resulting in ﬁnancial
stress, depression, physical illness, and decreased
quality of life.1.Creutzfeldt-Jakob disease (CJD), a
human prion disease, is clinically characterized by
rapidly progressive dementia.2 It is believed to be
caused by spongiform changes due to the accumulation of the scrapie isoform of the prion protein
(PrPSc) in the brain.2 This rare neurodegenerative
disorder occurs in just 1 in 1 million people worldwide, or about 350 cases annually in the US.3 A

deﬁnitive diagnosis requires a brain biopsy or autopsy.3 With the updated diagnostic criteria, clinicians can make a presumptive premortem diagnosis
to allow for planning and goals of care discussions
and focus on optimizing function.
The Center for Disease Control has updated
diagnostic criteria that divide the diagnosis of CJD
into possible, probable, or deﬁnite by using a
multimodal approach. For a probable diagnosis, a
rapidly progressive cognitive impairment must be
present with at least two of the following: myoclonus, visual or cerebellar problems, pyramidal or
extrapyramidal features, or akinetic mutism. If these
symptoms are present along with at least one of the
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following: periodic sharp wave complexes on electroencephalogram, hyperintensity signals on diffusion-weighted imaging in the basal ganglia or at
least two regions in the cerebral cortex, positive CSF
14-3-3, or positive CSF for real-time quakinginduced conversion (RT-QuIC), then the patient
has a probable diagnosis.4 A deﬁnitive diagnosis
can only be made with immunohistochemical or
neuropathological brain ﬁndings via biopsy at autopsy.4 (see Tables 1 and 2)
Although considerable diagnostic advances have
been made throughout the years, CJD remains a
fatal and non-curable neurodegenerative disease
with few therapeutic options. An early presumptive
diagnosis is helpful to guide clinicians in supporting
families in their decision-making process and transition them into a safe and appropriate discharge.
CJD management is complex and often extends
outside the physical domain, and many unique
features of prion diseases complicate clinical care.
Given the poor prognosis, rapid deterioration, and
difﬁculty in diagnosing this rare condition with
limited life expectancy, clinicians may be hesitant to
transition CJD patients to inpatient rehabilitation.
When time is limited, they must weigh the pros and
cons of continuing hospitalization. Therefore, the
goal of this report is to help highlight the role
inpatient rehabilitation can have on CJD patients
and their families.

2. Case presentation
2.1. Hospital summary
A 62-year-old male with no signiﬁcant past medical history and a recent admission for a mechanical
fall resulting in an L1 compression fracture was
readmitted to the acute care hospital for rapidly
debilitating tremors, visual hallucinations, and a
recurrent fall. On more detailed history, the patient
was noted to have progressive memory loss with
cognitive deﬁcits, 20 pounds of unintentional weight
loss, myoclonus, high-frequency low amplitude
bilateral hand tremor, hypophonia, hypnagogic visual hallucinations, and postural instability with
frequent falls over the past 3e4 months.
Initial admission labs were unremarkable, and a
non-contrast CT head did not show acute abnormalities. Given suspicion for CJD, an EEG was
performed that showed no epileptiform discharges
and speciﬁcally no periodic sharp wave complexes
that are classic for CJD. Brain MRI found areas of
hyperintensity signals within the bilateral occipital
and posterior temporal lobes on diffusion-weighted
imaging. A lumbar puncture was performed to
obtain studies for a paraneoplastic panel, autoimmune encephalitis, and prion disease, all of which
were pending when the patient was ready for
discharge.

Table 1. Diagnosis of sporadic Creutzfeldt-Jakob disease.
Possible

Probable

Deﬁnitive

1. Progressive dementia AND
at least two of the following:
a. Akinetic mutism
b. Myoclonus
c. Visual or cerebellar signs
d. Pyramidal or
extrapyramidal signs

1. Presence of a neuropsychiatric disorder
PLUS positive CSF real time-quaking-induced
conversion (RT-QuIC).

Neuropathological conﬁrmation via
brain biopsy of any of the following three
techniques:
1. Immunocyto-chemical
2. Western blot conﬁrmed
protease-resistant PrP
3. Presence of scrapie-associated ﬁbrils

AND

2. Absence of positive results on
CSF RT-QuIC, CSF 14-3-3, EEG,
or MRI ﬁndings.
3. Duration less than two years
4. Exclusion of other causes in
a complete diagnostic workup

OR

1. Rapidly progressive dementia
AND at least two of the following:
a. Akinetic mutism
b. Myoclonus
c. Visual or cerebellar signs
d. Pyramidal or extrapyramidal signs

AND

at least 1 of the following:

1. EEG with periodic sharp wave complexes
2. CSF positive 14-3-3
3. Hyperintensity signaling in the basal
ganglia (caudate/putamen) or at least two
cortical regions (temporal, parietal, occipital)
on diffusion-weighted imaging (DWI) or
ﬂuid-attenuated inversion recovery (FLAIR).

exclusion of other causes in
a complete diagnostic workup

AND

The table has been adapted from CDC 2018 CJD diagnostic criteria.9
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Table 2. Nonpharmacologic and pharmacologic interventions for common prion disease symptoms6e8.
Symptom

Management

Myoclonus

Decrease sensory stimulation, maintaining a quiet environment, antiepileptic medications (levetiracetam and sodium valproate), long-acting benzodiazepines (clonazepam and diazepam) if
tolerated.
Cognitive behavioral therapy, family intervention, coping strategies, exposure therapy, acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine).
Good sleep hygiene, routine sleep and wake schedule, avoid blue light 60-30 min before bedtime.
Melatonin agonists, benzodiazepines, and antidepressants with sedating effects (trazodone and
mirtazapine).
Antipsychotic medications (quetiapine, risperidone, or olanzapine).
Counseling, pastoral care, art, music, and aroma therapy. Antidepressants (SSRI and SNRIs).
Pill dispenser, cognitive aids, structured daily routine, offer simple choices, label needed objects,
remove clutter or unnecessary objects, use calm and reassuring tone. Acetylcholinesterase inhibitors
(donepezil, rivastigmine, galantamine).
Bladder training, ﬂuid schedule, plan toileting schedule, bladder diary, and condom catheter as
appropriate.
Increase ﬂuid intake, ﬁber diet, bowel diary, and scheduled toileting.
Thickened ﬂuids and pureed food. Appropriate positioning with aspiration protocols.
Place objects in easy reach of the unaffected side.

Visual Hallucinations
Insomnia

Psychosis/Aggression/Agitation
Depression/Anxiety
Dementia

Urinary incontinence
Constipation
Dysphagia
Visual Impairment/Cortical
Blindness
Spasticity
Neuropathic Pain
Orthostatic Hypotension

Passive movement exercises, massage, acupuncture, botulinum toxin injections, antispasmodic
medications (baclofen, dantrolene, tizanidine, benzodiazepines).
Desensitization techniques (TENS, hot/cold therapy), gabapentin, pregabalin, amitriptyline.
Increase ﬂuid intake, abdominal binder, gradual positioning of body maneuvers, TED stockings,
reduce inactivity, midodrine, ﬂudrocortisone, decrease or avoid medications that lower blood
pressure, for example (nitrates, diuretics, narcotics, antihypertensive agents, and antiparkinsonian
agents).

A probable diagnosis of Creutzfeldt-Jakob disease
was made, and given his fall risk and recent
reduction in functional status, the patient was
transferred to an acute rehabilitation facility to
maximize mobility, cognition and coordinate goals
of care. Approximately three weeks after obtaining
the CSF samples, the CSF results for prion disease
were positive for 14-3-3 protein and RT-QuIC, thus
conﬁrming a probable diagnosis of CreutzfeldtJakob disease with >98% likelihood.
2.2. Acute inpatient rehabilitation summary
Initial assessment revealed the patient to be at
moderate assistance for transfers, ambulation, bed
mobility, and most activities of daily living. The
patient underwent a neurocognitive impairment
assessment based on prior education level using the
St. Louis University Mental Score and attained a
score of 18 out of 30, suggestive of dementia. Using
the Boston 6-clicks score to assess basic mobility, the
patient scored 12 out of 24, indicating a lower level
of independent function. He underwent a comprehensive, multidisciplinary rehabilitation for ambulatory dysfunction, decreased activities of daily
living (ADL), strength, postural instability, endurance, and severe cognitive impairment.
Rehabilitation focused on ADL retraining, cognition, gait training, strength, endurance, balance,
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safety, family training, and end-of-life care. The
patient underwent therapeutic exercise, gait
training, neuromuscular reeducation, cognitive
behavioral therapy, and voice therapy throughout
his 14-day rehabilitation stay. Midodrine, compression stockings, and an abdominal binder managed
his signiﬁcant orthostatic hypotension, and physical
therapy worked on his retropulsion with transfers.
His inpatient rehabilitation course was complicated
by heightened anxiety above his baseline from his
new diagnosis, which was managed by escitalopram
and cognitive behavioral therapy with a rehabilitation neuropsychologist. Myoclonus was managed by
sodium valproate and clonazepam. Educational resources and healthcare provider communication
addressed family and patient concerns about diagnosis, transmissibility, and genetic involvement.
Palliative medicine focused on realistic expectations,
transitioning to end-of-life care, and establishing a
living will and power of attorney. He was provided
with a rolling walker, home health services, and
coordinated care with physicians at discharge.

3. Outcomes/Results
Overall, signiﬁcant functional gains were obtained
at discharge. The patient transitioned from moderate assistance (50% patient effort and 50% caregiver
effort) to minimal assistance (75% patient effort and
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25% caregiver effort) with most activities of basic
daily living, bed mobility, and transfers. The patient
was also contact guard assist (100% patient effort
and 0% caregiver effort) with a rolling walker for
100 ft. The patient's functional improvements were
sufﬁcient to meet goals to return home for a safe
discharge.

4. Discussion
Currently, there are no approved treatments for
managing the causes of prion disease, and treatment focuses on minimizing symptoms and maintaining the quality of life. One study suggests that
the most problematic symptoms of prion disease
include coordination and mobility, personal care
and incontinence, communication, eating and
swallowing, behavior and mood, and cognitive and
memory.5 These issues can be addressed in the
acute rehabilitation unit by a multidisciplinary
team. A physiatrist can help the caregiver learn
optimal and new approaches for managing the patient's functional and basic needs. This transition of
care to a rehabilitation unit can facilitate coordinated care before discharge, arrange for hospice
evaluation, counsel families on the end of life and
ﬁnancial matters, and offer social support.6 While at
the rehabilitation hospital, physiatrists and their
healthcare professionals can utilize speciﬁc pharmacologic and nonpharmacologic interventions to
minimize common and debilitating symptoms that
prion disease patients often experience throughout
their disease course. The primary focus is to reduce
the patient's symptoms and improve quality of life.
The non-pharmacological and pharmacological
approaches to treat the varying symptoms one may
exhibit with progressive neurodegenerative disease
are complex. Myoclonus, orthostatic hypotension,
and anxiety were this case's most signiﬁcant symptomatic medical obstacles. The patient was started
on sodium valproate 250 mg daily with clonazepam
0.5 mg at bedtime to combat his myoclonus disturbance. The added effect of moving his room to the
end of the rehabilitation unit to decrease sensory
stimulation ultimately abated this symptom.
Orthostatic hypotension management was a significant barrier in this clinical scenario because it
placed safety concerns on the patient's therapy
plans. This was ultimately resolved with midodrine
5 mg three times per day, along with an abdominal
binder and compression stockings. Lastly, the patient's heightened anxiety about his future and the
future of his family's stability was managed with
escitalopram 20 mg daily, pastoral/chaplain discussions, and cognitive behavioral therapy with the
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neuropsychologist. The combination of pharmacological and non-pharmacological approaches
proved to be the best method in this clinical scenario. However, this paper's authors would argue
that the most critical component of this patient's
rehabilitation was caregiver support, family
training, medical education, initiating palliative
care, establishing home health services, providing
mobility assistive devices, and modifying the living
arrangements to meet his functional needs. The
patient made substantial improvements in his ability to perform ADLs requiring minimal assistance
for ambulation, transfers, bathing, and toileting on
discharge. As a result, he and his family successfully
managed his care out of their home. The patient
passed away six months after discharge from the
rehabilitation hospital in his home under the supervision of a hospice team. A subsequent brain
autopsy at the National Prion Surveillance Center
(www.cjdsurveillance.com) conﬁrmed the presence
of the prion protein, thus conﬁrming deﬁnite CJD.
There is no research published on outcomes or
management of CJD patients in an acute rehabilitation setting, likely due to the rarity of the disease.
Therefore, it is unknown when to admit CJD patients
appropriately, how long they should be admitted,
and how effective rehabilitation can be for those individuals. Suppose this individual was at the end of
his disease course. One may argue this individual
has limited and valuable time to spend with loved
ones, so 14 days of acute rehabilitation would take
away from his home experience, and possibly no
functional gains would be obtained. This will have to
be a clinical decision made by the health provider
based on the patient's clinical presentation, family
guidance, and patient preference, as there is minimal
to no objective data until this case report.
In conclusion, this case report highlights the
unique challenges of individuals and their families
who suffer from prion disease and reviews ways to
manage these barriers through non-pharmacological and pharmacological treatment options at an
inpatient rehabilitation facility. A 14-day inpatient
rehabilitation stay improved this patient's functional
status, trained his caregiving family members, coordinated home health services, and established a
relationship with palliative care in anticipation of
eventual hospice needs. When a diagnosis of probable CJD is made, an inpatient rehabilitation facility
can assist in decreasing the caregiver burden and
support the psychosocial needs of CJD patients
while improving physical function. Ultimately, the
transition of care to an acute rehabilitation hospital
can be important to families and individuals
affected by prion disease.
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